Literature DB >> 2029497

Quantitative studies of transfer in vivo of low density, Sf 12-60, and Sf 60-400 lipoproteins between plasma and arterial intima in humans.

M Shaikh1, R Wootton, B G Nordestgaard, P Baskerville, J S Lumley, A E La Ville, J Quiney, B Lewis.   

Abstract

To assess the potential of various plasma lipoprotein classes to contribute to the lipid content of the arterial intima, influx and efflux of these plasma lipoprotein fractions into and from the intima of human carotid arteries were measured in vivo. While low density lipoprotein (LDL) is known to transfer from plasma into the arterial wall, there is less information on the atherogenic potential of lipoproteins of intermediate density (Sf 12-60) or of very low density (Sf 60-400). Aliquots of the same lipoprotein (LDL, Sf 12-60 lipoprotein particles, or Sf 60-400 lipoprotein particles) iodinated with iodine-125 and iodine-131 were injected intravenously 18-29 hours and 3-6 hours, respectively, before elective surgical removal of atheromatous arterial tissue, and the intimal clearance of lipoproteins, lipoprotein influx, and fractional loss of newly entered lipoproteins were calculated. Intimal clearance of Sf 60-400 particles was not detectable (less than 0.3 microliter x hr-1 x cm-2), whereas the average value for both LDL and Sf 12-60 lipoprotein particles was 0.9 microliter x hr-1 x cm-2. Since the fractional loss of newly entered LDL and Sf 12-60 lipoprotein particles was also similar, the results suggest similar modes of entry and exit for these two particles. However, due to lower plasma concentrations of Sf 12-60 lipoproteins as compared with LDL, the mass influx of cholesterol in the Sf 12-60 particles was on the order of one 10th of that in LDL, and that of apolipoprotein B was about one 20th.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2029497     DOI: 10.1161/01.atv.11.3.569

Source DB:  PubMed          Journal:  Arterioscler Thromb        ISSN: 1049-8834


  30 in total

Review 1.  Postprandial lipemia and cardiovascular disease.

Authors:  Dianne Hyson; John C Rutledge; Lars Berglund
Journal:  Curr Atheroscler Rep       Date:  2003-11       Impact factor: 5.113

Review 2.  IDL, VLDL, chylomicrons and atherosclerosis.

Authors:  B G Nordestgaard; A Tybjaerg-Hansen
Journal:  Eur J Epidemiol       Date:  1992-05       Impact factor: 8.082

3.  Triglyceride-Rich Lipoprotein Cholesterol, Small Dense LDL Cholesterol, and Incident Cardiovascular Disease.

Authors:  Edward K Duran; Aaron W Aday; Nancy R Cook; Julie E Buring; Paul M Ridker; Aruna D Pradhan
Journal:  J Am Coll Cardiol       Date:  2020-05-05       Impact factor: 24.094

4.  [Clinical value of apolipoprotein B versus low-density lipoprotein cholesterol in assessing risks of coronary artery disease].

Authors:  Si Chen; Jin-Zhen Zhao; Jing Hu; Zhi-Gang Guo
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2017-07-20

5.  Molecular biology of atherosclerosis.

Authors:  Elmo Mannarino; Matteo Pirro
Journal:  Clin Cases Miner Bone Metab       Date:  2008-01

Review 6.  The role of hypertriglyceridemia in atherosclerosis.

Authors:  Ngoc-Anh Le; Mary F Walter
Journal:  Curr Atheroscler Rep       Date:  2007-08       Impact factor: 5.113

Review 7.  Triglycerides as vascular risk factors: new epidemiologic insights.

Authors:  William B Kannel; Ramachandran S Vasan
Journal:  Curr Opin Cardiol       Date:  2009-07       Impact factor: 2.161

8.  One year experience in the treatment of familial hypercholesterolaemia with simvastatin.

Authors:  J Quiney; G F Watts; M Kerr-Muir; B Slavin; B Lewis
Journal:  Postgrad Med J       Date:  1992-07       Impact factor: 2.401

9.  Comparison of nonfasting and fasting lipoprotein subfractions and size in 15,397 apparently healthy individuals: An analysis from the VITamin D and OmegA-3 TriaL.

Authors:  Zareen M Farukhi; Olga V Demler; Michael P Caulfield; Krishnaji Kulkarni; Jay Wohlgemuth; Michael Cobble; Heike Luttmann-Gibson; Chunying Li; John R Nelson; Nancy R Cook; Julie E Buring; Ronald M Krauss; JoAnn E Manson; Samia Mora
Journal:  J Clin Lipidol       Date:  2020-02-21       Impact factor: 4.766

Review 10.  Advances in lipid-lowering therapy through gene-silencing technologies.

Authors:  Børge G Nordestgaard; Stephen J Nicholls; Anne Langsted; Kausik K Ray; Anne Tybjærg-Hansen
Journal:  Nat Rev Cardiol       Date:  2018-02-08       Impact factor: 32.419

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.